VXRT Vaxart, Inc.
Listings ·
Nasdaq told Vaxart on September 19, 2025 that its common stock will be delisted after the company withdrew a reverse stock split proposal that a hearings panel had made a condition of continued listing. Trading on Nasdaq was suspended on July 8, 2025.
Vaxart agreed on March 21, 2025 to sell up to $50 million of common stock through Citizens JMP Securities and B. Riley Securities, which may each receive a commission of up to 3% of gross sales. The stock closed at $0.5754 on March 17, 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $237.3 million | $28.7 million |
| Research and development | $201.6 million | $74.2 million |
| Net income (loss) | $16.3 million | -$66.9 million |
| Cash from operations | $7.7 million | -$44.8 million |
| Cash and equivalents | $53.8 million | $25.2 million |
| Short-term investments | $10.0 million | $26.5 million |
Our latest story on this, dated Sep 19, 2025: "Vaxart to be delisted from Nasdaq after missing hearings panel conditions". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 19, 2025: "Vaxart to be delisted from Nasdaq after missing hearings panel conditions". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 21, 2025: "Vaxart sets up $50,000,000 at-the-market stock program". The story links the filing or release it is based on. Read the story.
Vaxart, Inc. trades under the ticker VXRT on OTC.
Vaxart, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Vaxart, Inc. is 72444. Its filings are on SEC EDGAR.
242,835,358 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Vaxart, Inc. under United States.
Our directory classifies Vaxart, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Vaxart, Inc. is US92243A2006.
aibio.space lists Vaxart, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$237.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Vaxart, Inc. reported net income of $16.3 million for the fiscal year ended Dec 31, 2025, and generated $7.7 million of cash from operations, per its annual report to the SEC.
$201.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,7.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio